Cipla share price has zoomed 8% and is presently trading at Rs 1,532.0.
Meanwhile, the BSE HEALTHCARE index is at 43,590.7 (up 1.1%).
Among the top gainers in the BSE HEALTHCARE index today are AJANTA PHARMA (up 2.9%) and POLY MEDICURE (up 2.4%).
Biocon (down 2.3%) and ASTRAZENECA PHARMA (down 0.7%) are among the top losers today.
Over the last one year, Cipla has moved up from Rs 1,193.1 to Rs 1,532.0, registering a gain of Rs 339.0 (up 28.4%).
On the other hand, the BSE HEALTHCARE index has moved up from 27,385.2 to 43,590.7, registering a gain of 59.2% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 195.2%), SUVEN PHARMACEUTICALS (up 127.2%) and Glenmark Pharma (up 124.8%).
Dear Reader: If You Invest in Midcap Stocks, this is for You
The BSE Sensex is at 79,820.3 (down 0.2%).
The top losers among the BSE Sensex today are Tech Mahindra (down 1.9%) and Infosys (down 1.7%). The most traded stocks in the BSE Sensex are Tata Steel and Tata Motors.
In the meantime, NSE Nifty is at 24,293.5 (down 0.2%). Tech Mahindra and Infosys are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 64,112.7 to 79,820.3, registering a gain of 15,707.7 points (up 24.5%).
Cipla net profit grew 13.0% YoY to Rs 13,060 million for the quarter ended September 2024, compared to a profit of Rs 11,558 million a year ago. Net sales rose 5.6% to Rs 70,510 million during the period as against Rs 66,782 million in July-September 2023.
For the year ended March 2024, Cipla reported 46.5% increase in net profit to Rs 41,553 million compared to net profit of Rs 28,355 million during FY23. Revenue of the company grew 13.3% to Rs 257,741 million during FY24.
The current Price to earnings ratio of Cipla, based on rolling 12 month earnings, stands at 27.6.
Equitymaster requests your view! Post a comment on "Cipla Gains 8%; BSE HEALTHCARE Index Up 1.1%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!